Celonic Group, a biologics CDMO, has signed a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for Commercial Supply.

Catumaxomab, a trifunctional bispecific monoclonal antibody, is specifically designed for the intraperitoneal treatment of malignant ascites in adult patients with epithelial cell adhesion molecule (EpCAM)-positive carcinomas. This treatment option is particularly valuable for those who are ineligible for conventional systemic anticancer therapies. Malignant ascites, a common complication of advanced-stage cancers, is characterized by an abnormal accumulation of fluid in the peritoneal cavity.

Under the terms of the multi-year commercial manufacturing agreement, Celonic Group will leverage its expertise in GMP manufacturing to produce catumaxomab at its manufacturing facility in Heidelberg, Germany.

Dr. Horst Lindhofer, CEO of LINDIS Biotech, commented: “Partnering with Celonic Group is a vital part of our mission to bring catumaxomab to patients suffering from malignant ascites and fill this unmet clinical need. With Celonic’s proven manufacturing capabilities and commitment to quality, we are confident in their ability to ensure a reliable and high-quality supply of our innovative therapy.”

Samanta Cimitan PhD, CEO of Celonic Group, added: “We are honored to collaborate with LINDIS Biotech on the production of catumaxomab. This partnership underscores our dedication to supporting the development and commercialization of groundbreaking biologics that address unmet medical needs.”